Compare GSK plc (GSK) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Raymond James Financial, Inc. — how do they compare? GSK plc trades at $52.75 (market cap $101.34B), while Raymond James Financial, Inc. trades at $168.24 (market cap $33.19B). The key difference: GSK plc is far larger — about 3.1× Raymond James Financial, Inc.'s market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | RJF | |
|---|---|---|
Market Cap | $101.34B | $33.19B |
Sector | Health | Financials |
52-Week High | $61.18 | $176.43 |
52-Week Low | $36.20 | $140.89 |
Enterprise Value | $121.95B | — |
Dividend Yield | 3.49% | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
Raymond James Financial (RJF) trades at $169.26, up 1.09% today, with a bullish technical outlook and consistent earnings beats in recent quarters. The stock shows strong revenue growth, reaching $13.84B in 2025, and maintains a net income margin of 14.83%. Analyst consensus is positive with a $176.83 price target, though cost pressures remain a concern amid record financial performance.
RJF presents a compelling investment case with solid fundamentals and upward momentum, but risks include expense growth and market volatility. The stock's valuation at a P/E of 16.08 offers room for appreciation if earnings growth persists, supported by institutional bullishness and strategic expansions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
